Clinical analysis of 30 cases of male breast cancer

doi:10.3877/cma.j.issn.1674-0807.2008.05.005

Abstract

Abstract:

Objective

To evaluate the clinical characteristics, therapeutic methods and prognosis of male breast cancer cases.

Methods

The clinical data of 30 patients diagnosed with male breast cancer were analyzed retrospectively. The survival rate was calculated by Kaplan-Meier.

Results

The 5-year overall survival rate was 67% in the group. The 5-year survival rate was 100% for stage Ⅰbreast cancer, 60% for stage Ⅱ, and 43% for stage Ⅲ, but no cases of stage Ⅳsurvived for 5 years. It was found by single-variant analysis that the tumor size(P=0.006), axillary lymph node status(P=0.013) and tumor stage(P=0.004)significantly influenced the outcome of the patients. Multi-variant Cox regression showed that tumor stage (P=0.009) was an independent factor.

Conclusion

The surgical treatment-based reasonable multi-modality therapy may improve the outcome of male breast cancer patients and will be standard care for these patients.Tumor stage is an independent prognostic factor.

Key words: Male breast cancer, Treatment, Prognosis

Chun-mei LIANG, Jun WANG, Ping WANG. Clinical analysis of 30 cases of male breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2008, 02(05): 18-21.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2008.05.005

https://zhrxbzz.cma-cmc.com.cn/EN/Y2008/V02/I05/18

Figures/Tables 1

References 12

[1]	O'Malley C D, Prehn A W, Shema S J, et al. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer,2002,94:2836 -2843.
[2]	叶静. 乳腺癌易感基因的研究进展. 癌症,2002,21:1035 -1039.
[3]	Krause W. Male breast cancer - an andrological disease: risk factors and diagnosis. Andrologia,2004,36:346 -354.
[4]	Giordano S H, Cohen D S, Buzdar A U, et al. Breast carcinoma in men: a population-based study. Cancer,2004,101:51 -57.
[5]	Murphy C E, Carder P J, Lansdown M R, et al. Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol,2006,32:44 -47.
[6]	Giordano S H, Perkins G H, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer,2005,104:2359 -2364.
[7]	Macdonald G, Paltiel C, Olivotto I A, et al. A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol,2005,16:1442 -1448.
[8]	田大龙,柏会明,杨树成,等.男性乳腺癌术后放射治疗疗效分析.肿瘤防治研究,2006,33:826 -828.
[9]	Chakravarthy A, Kim C R. Post-mastectomy radiation in male breast cancer. Radiother Oncol,2002,65:99 -103.
[10]	张保宁,张慧明.第30 届圣·安东尼奥乳腺癌研讨会有关芳香化酶抑制剂的应用报道. 中华乳腺病杂志(电子版),2008,2:128 -131.
[11]	Zabolotny B P, Zalai C V, Meterissian S H. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol,2005,90:26 -30.
[12]	吴斌,周业江,时徳,等. 男性乳腺癌的治疗及预后因素分析:附37 例报告.中国普通外科杂志,2004,13:321 -323.

临床因素	例数	占总体比例(%)	5年生存率(%)	P值
年龄/岁
＜60	12	40.0	75	0.613
≥60	18	60.0	61
病变部位
左侧	13	43.3	69	0.350
右侧	17	57.7	64
肿瘤大小/cm
＜5	21	70.0	81	0.006
≥5	9	30.0	33
腋窝淋巴结转移情况
无转移	20	66.7	80	0.013
有转移	10	33.3	40
TNM分期
Ⅰ+Ⅱ	21	70.0	81	0.004
Ⅲ+Ⅳ	9	30.0	33
ER/PR^a
均阳性	14	73.7	67	0.979
均阴性	3	15.8	64
手术方式
根治术	16	53.3	63	0.322
改良根治术	12	40.0	75
其他	2	6.7	50
术后放射治疗
无	20	66.7	69	0.217
有	10	33.3	66
化疗
无	6	20.0	46	0.153
有	24	80.0	67
内分泌治疗
无	18	60.0	52	0.204
有	12	40.0	71

临床因素	例数	占总体比例(%)	5年生存率(%)	P值
年龄/岁
＜60	12	40.0	75	0.613
≥60	18	60.0	61
病变部位
左侧	13	43.3	69	0.350
右侧	17	57.7	64
肿瘤大小/cm
＜5	21	70.0	81	0.006
≥5	9	30.0	33
腋窝淋巴结转移情况
无转移	20	66.7	80	0.013
有转移	10	33.3	40
TNM分期
Ⅰ+Ⅱ	21	70.0	81	0.004
Ⅲ+Ⅳ	9	30.0	33
ER/PR^a
均阳性	14	73.7	67	0.979
均阴性	3	15.8	64
手术方式
根治术	16	53.3	63	0.322
改良根治术	12	40.0	75
其他	2	6.7	50
术后放射治疗
无	20	66.7	69	0.217
有	10	33.3	66
化疗
无	6	20.0	46	0.153
有	24	80.0	67
内分泌治疗
无	18	60.0	52	0.204
有	12	40.0	71

[1]	Baicheng Yi, Xuguang Li, Rongrong Wang, Xinxuan Wang. Treatment of calcified root canals in upper anterior teeth using digital 3D-printing guides：A clinical report of two cases [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2024, 18(06): 385-390.
[2]	Jie Xu, Yajun Li, Junwei Han. Comparison of the efficacy of radical laparoscopic total gastrectomy in the treatment of overweight gastric cancer with two approaches [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 19-22.
[3]	Huazhi Li, Guang Cao, Diangang Liu, Yajing Zhang. Clinical comparison of descending hepatectomy with different approaches for primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 52-55.
[4]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[5]	Daiqin Li, Peijie Liu. Value of dynamic enhanced magnetic resonance imaging in evaluating the efficacy and prognosis of middle and advanced low rectal cancer after concurrent chemoradiotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 100-103.
[6]	Hao Chen, Meng Wang. Advances in clinicopathological features and treatment options of sig-ring cell carcinoma of the stomach [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 108-111.
[7]	Wei Li, Zijian Song, Yancheng Lai, Rui Zhou, Han Wu, Longxin Deng, Rui Chen. The current state and prospects of artificial intelligence applied to prognosis prediction in prostate cancer patients [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 541-546.
[8]	Yifan Li, Diwen Zhu, Weixin Ren, Yingjun Bao, Junpeng Gu, Haixiao Zhang, Gengfei Cao, Weizheng Ji. Role of serum GP73 level in the evaluation of TACE efficacy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 825-830.
[9]	Xiaoling Guan, Wenying Zhou, Hongping Chen. Predictive value of PTAAR for short-term prognosis of patients with hepatitis B virus-related acuteon-chronic liver failure [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 841-845.
[10]	Runjin Zhang, Pan Yang, Yansi Lin, Zunlong Liu, Jianping Liu, Xiaoyan Jin. Epstein-Barr virus-associated cholangiocarcinoma complicated with multiple metastases: a case report and Chinese literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 865-869.
[11]	Xiaopeng Chen, Jiani Wang, Qinghai Lian, Jiumei Yang. Expression of VOPP1 in hepatocellular carcinoma and its relationship with prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 876-882.
[12]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of anal cancer （2024 Edition） [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 441-449.
[13]	Jiagang Han, Zhenjun Wang. The treatment strategies for obstructive left-sided colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 450-458.
[14]	Tianyu Wu, Zixuan Liu, Puxin Yang, Siming Jia, Kai Ding, Xiaodong Cheng, Yonglong Li, Wei Chen, Hongzhi Lyu, Qi Zhang. Progress in Conservative Treatment of Lumbar Disc Herniation [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 379-384.
[15]	Zhaorong Guo, Xinguang Wang, Yiqiang Liu, Yingjian He, Lize Wang, Yang Yang, Xing Wang, Wei Cao, Chongshan Gu, Tie Fan, Jinfeng Li, Zhaoqing Fan. Clinicopathologic characteristics and prognostic risk factors of different subtypes of phyllodes tumor of the breast [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 524-532.

Please choose a citation manager

Content to export